On November 11, Centrus rose 5.67% in Regular Trading, trading at $116.265/share, with turnover of $23.6811 million.
The latest identifiable catalyst was the company’s announcement that Kevin Graney joined the board, while recent analyst sentiment remained supportive after Roth Capital and Canaccord Genuity upgraded the stock to Buy.
In the recent backdrop, Roth Capital lifted its rating from Neutral to Buy with a $115 price target, and Canaccord Genuity also upgraded the stock to Buy. That followed a weaker quarterly release on November 4, when adjusted EPS came in at a loss of $0.49 and revenue was $55.5 million, both below expectations, suggesting the current move is more tied to sentiment repair and event-driven support than to fresh earnings strength.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments